PolyPid’s D-PLEX₁₀₀ Receives the US FDA’s Breakthrough Therapy Designation for the Prevention of Surgical Site Infections in Colorectal Surgery

PolyPid’s D-PLEX₁₀₀ Receives the US FDA’s Breakthrough Therapy Designation for the Prevention of Surgical Site Infections in Colorectal Surgery

PolyPid’s D-PLEX₁₀₀ Receives the US FDA’s Breakthrough Therapy Designation for the Prevention of Surgical Site Infections in Colorectal Surgery

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post